Happy City Holdings Limited Announces Pricing of $5.5 million Initial Public Offering and Listing on Nasdaq
Hong Kong, June 23, 2025 (GLOBE NEWSWIRE) — Happy City Holdings Limited (Nasdaq: HCHL) (the 'Company'), an established all-you-can-eat hotpot restaurant operator in Hong Kong , today announced the pricing of its initial public offering (the 'Offering') of 1,100,000 Class A ordinary shares (the 'Class A Ordinary Shares'), at a price of $5.00 per Class A Ordinary Share (the 'Offering Price').
The Class A Ordinary Shares are expected to begin trading on the Nasdaq Capital Market on June 24, 2025 under the symbol 'HCHL.' The Offering is expected to close on June 25, 2025, subject to the satisfaction of customary closing conditions.
The Company expects to receive aggregate gross proceeds of US$5.5 million from the Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 165,000 Class A Ordinary Shares of the Company, at the Offering Price, representing 15% of the Class A Ordinary Shares sold in the Offering (the 'Over-allotment Option'). Assuming that the Over-allotment Option is exercised, the Company is expected to receive gross proceeds amounting to $6.325 million, before deducting underwriting discounts and commissions and estimated offering expenses.
The Company intends to use the net proceeds for its business expansion in Hong Kong and Southeast Asia region and working capital and general corporate purposes.
The Offering is conducted on a firm commitment basis. Dominari Securities LLC is acting as the representative of the underwriters, with Revere Securities LLC and Pacific Century Securities LLC acting as the co-underwriters (collectively, the 'Underwriters') for the Offering. Ortoli Rosenstadt LLP, Ogier, David Fong & Co. and China Commercial Law Firm are acting as United States, British Virgin Islands, Hong Kong and People's Republic of China legal counsels to the Company, respectively. AOGB CPA LIMITED is acting as the reporting accountants of the Company. VCL Law LLP is acting as legal counsel to the Underwriters for the Offering.
The Offering is being conducted pursuant to the Company's Registration Statement on Form F-1 (File No. 333- 285856) previously filed with, and subsequently declared effective by the U.S. Securities and Exchange Commission (the 'SEC') on May 30, 2025. The Offering is being made only by means of a prospectus. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, copies of the prospectus relating to the Offering may be obtained, when available, from Dominari Securities LLC by email at [email protected], by standard mail to Dominari Securities LLC, 725 Fifth Avenue, 23rd Floor New York, NY 10022, or by telephone at (212) 393-4500; or from Revere Securities LLC by email at [email protected], by standard mail to Revere Securities LLC, 560 Lexington Avenue, 16th Floor, New York, NY 10022, or by telephone at +1 (212) 688-2350; or from Pacific Century Securities LLC by email at [email protected], by standard mail to Pacific Century Securities, LLC, 60-20 Woodside Avenue Ste 211 Queens, NY 11377, or by telephone at 212-970-8868.
Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, and no sale of these securities may be made in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Happy City Holdings Limited
Headquartered in Hong Kong, we are a restaurant operator that operates three all-you-can-eat hotpot restaurants in Hong Kong serving mixed style, Shabu Shabu-style and Thai-style specialty hotpot. Through our restaurants that are located in various prime locations in Hong Kong, our unique brand image, and our strong commitment to food quality, we offer an immersive dining experience to our customers.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations, including the trading of its Class A Ordinary Shares or the closing of the Offering. Investors can find many (but not all) of these statements by the use of words such as 'approximates,' 'believes,' 'hopes,' 'expects,' 'anticipates,' 'estimates,' 'projects,' 'intends,' 'plans,' 'will,' 'would,' 'should,' 'could,' 'may' or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company's final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company's securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contacts
Happy City Holdings Limited Investor Relations
Email: [email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
32 minutes ago
- Business Wire
Law Offices of Howard G. Smith Encourages Tempus AI, Inc. (TEM) Investors To Inquire About Securities Fraud Class Action
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Tempus AI, Inc. ('Tempus' or the 'Company') (NASDAQ: TEM) common stock between , inclusive (the 'Class Period'). Tempus investors have until August 12, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TEMPUS AI, INC. (TEM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 28, 2025, Spruce Point Capital published a report alleging, among other things, that Tempus' AI capabilities were overstated, and that Company's recent financial guidance revision revealed weakness in its core operations. On this news, Tempus' stock price fell $12.67, or 19.2%, to close at $53.20 per share on May 28, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable 'pass-through payment' via a joint agreement between it, the Company and Pathos AI; (5) the foregoing issues revealed weakness in core operations and revenue prospects; and (6) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. Contact Us To Participate or Learn More: If you purchased Tempus common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
an hour ago
- Business Wire
ArrePath Announces Closing of Their Next Financing Round
PRINCETON, N.J.--(BUSINESS WIRE)--ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor'easter Ventures, and new investor AB Magnitude. 'We are grateful for the ongoing support of our strong investor base and welcome our new investor, AB Magnitude, to ArrePath,' said Kevin Krause, President and CEO. 'This raise, in combination with our recently announced non-dilutive funding awards from PACE and CARB-X, enables ArrePath to advance our lead program, AP-001, towards development candidate nomination and eventual Phase 1 studies. In addition, the new funding will support expansion of our novel compounds active against non-tuberculous mycobacteria.' Following the closing of this financing, ArrePath concluded a search for a new Chair of the Board of Directors with the appointment of Diego Miralles, M.D. Dr. Miralles comes to ArrePath with extensive experience in the biotech and pharmaceutical industry in many strategic, development and leadership roles. He was recently nominated to the Board of Directors of Contineum (NASDAQ: CTNM) and serves on the Board of Artiva (NASDAQ: ARTV). Dr. Miralles, an Infectious Diseases trained clinician and scientist, has extensive executive experience including as CEO of AZURNA Therapeutics, Inc., Laronde, Inc., and Vividion Therapeutics, Inc, and President of Adaptive Therapeutics. Previous to these roles, Dr. Miralles held various senior executive and R&D leadership positions at Johnson & Johnson. Dr. Miralles received his M.D. degree from the University of Buenos Aires, completed his residency in Internal Medicine at the Mayo Clinic and a fellowship in Infectious Diseases at The New York Hospital/Cornell University and was on the faculty at Duke University. 'We are excited to welcome Dr. Miralles to the ArrePath Board of Directors,' said Kevin Krause. 'His decades of experience as an executive and board member in both private and public companies, along with his proven experience scaling emerging biotech companies, will provide invaluable insights and experience as we approach several near-term inflection points for ArrePath. I look forward to working with him as the company evolves into the next phase of growth.' 'I am really excited to join Kevin Krause, our outstanding newly appointed CEO, and the Board at ArrePath,' said Diego Miralles. 'The company's AI discovery platform which, coupled with the team's deep experience in antimicrobial development, will enable us to bring forward superior products to address unmet needs in antimicrobials. Recent approvals in antimicrobials demonstrate the continued need for improved products, a space where ArrePath will become a leader.' About ArrePath ArrePath combines the power of human intelligence with AI/ML to address the challenge of efficient drug discovery, which is a complex optimization process paired with an unimaginable number of chemical possibilities. Our AI/ML platform couples virtual and experimental compound design and testing to create efficiency at identifying novel compounds that are both active and have the attributes required to progress. To date, we have identified antibiotic hits active against three clinically novel targets. Of these, we are progressing AP-001 to focus on the large outpatient UTI market and a hospital avoidance strategy plus the potential for step-down from hospital-based IV therapies. We also have discovered multiple novel compound families active against non-tuberculous Mycobacteria (NTM). For more information on ArrePath's innovative work and mission, please visit
Yahoo
an hour ago
- Yahoo
ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair
PRINCETON, N.J., June 24, 2025--(BUSINESS WIRE)--ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor'easter Ventures, and new investor AB Magnitude. "We are grateful for the ongoing support of our strong investor base and welcome our new investor, AB Magnitude, to ArrePath," said Kevin Krause, President and CEO. "This raise, in combination with our recently announced non-dilutive funding awards from PACE and CARB-X, enables ArrePath to advance our lead program, AP-001, towards development candidate nomination and eventual Phase 1 studies. In addition, the new funding will support expansion of our novel compounds active against non-tuberculous mycobacteria." Following the closing of this financing, ArrePath concluded a search for a new Chair of the Board of Directors with the appointment of Diego Miralles, M.D. Dr. Miralles comes to ArrePath with extensive experience in the biotech and pharmaceutical industry in many strategic, development and leadership roles. He was recently nominated to the Board of Directors of Contineum (NASDAQ: CTNM) and serves on the Board of Artiva (NASDAQ: ARTV). Dr. Miralles, an Infectious Diseases trained clinician and scientist, has extensive executive experience including as CEO of AZURNA Therapeutics, Inc., Laronde, Inc., and Vividion Therapeutics, Inc, and President of Adaptive Therapeutics. Previous to these roles, Dr. Miralles held various senior executive and R&D leadership positions at Johnson & Johnson. Dr. Miralles received his M.D. degree from the University of Buenos Aires, completed his residency in Internal Medicine at the Mayo Clinic and a fellowship in Infectious Diseases at The New York Hospital/Cornell University and was on the faculty at Duke University. "We are excited to welcome Dr. Miralles to the ArrePath Board of Directors," said Kevin Krause. "His decades of experience as an executive and board member in both private and public companies, along with his proven experience scaling emerging biotech companies, will provide invaluable insights and experience as we approach several near-term inflection points for ArrePath. I look forward to working with him as the company evolves into the next phase of growth." "I am really excited to join Kevin Krause, our outstanding newly appointed CEO, and the Board at ArrePath," said Diego Miralles. "The company's AI discovery platform which, coupled with the team's deep experience in antimicrobial development, will enable us to bring forward superior products to address unmet needs in antimicrobials. Recent approvals in antimicrobials demonstrate the continued need for improved products, a space where ArrePath will become a leader." About ArrePath ArrePath combines the power of human intelligence with AI/ML to address the challenge of efficient drug discovery, which is a complex optimization process paired with an unimaginable number of chemical possibilities. Our AI/ML platform couples virtual and experimental compound design and testing to create efficiency at identifying novel compounds that are both active and have the attributes required to progress. To date, we have identified antibiotic hits active against three clinically novel targets. Of these, we are progressing AP-001 to focus on the large outpatient UTI market and a hospital avoidance strategy plus the potential for step-down from hospital-based IV therapies. We also have discovered multiple novel compound families active against non-tuberculous Mycobacteria (NTM). For more information on ArrePath's innovative work and mission, please visit View source version on Contacts ArrePath Reena
